Changing breast cancer adjuvant treatment: determining factors in Côte d'Or (France) from 1982 to 1990;Facteurs déterminant les traitements adjuvants du cancer du sein dans le département de la Côte d'Or entre 1982 et 1990. Registre des cancers gynécologiques de Côte d'Or

Bulletin du Cancer

Volumn 83, Issue 1, 1996, Pages 54-62

  Coudert, B ^b   Chaplain, G ^a,b   Milan, C ^c   Janoray, P ^d  

^a Registre Cancers Digestifs Cote d'Or   (France)

^b Service de Radiotherapie   (France)

^c INSERM   (France)

^d Centre Radiotherapie du Parc   (France)

Author keywords

Adjuvant treatment; Breast carcinoma; Cancer registry; Changing treatments

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; FEMALE; FRANCE; HUMAN; METASTASIS; MIDDLE AGED; PATHOLOGY; QUALITY CONTROL; REGISTER; REGRESSION ANALYSIS; RISK; STATISTICS; TREATMENT OUTCOME; ADJUVANT THERAPY; BREAST CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FRANCE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ODDS RATIO; QUALITY CONTROL; REGISTRIES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 0030054126     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Berrino F, Sant M, Verdecchia A et al. Survival of cancer patients in Europe. The EUROCARE study. Lyon IARC Scientific publication, 1995;132
2. Bonnadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992;52:2127-37
3. Chaplain G, Barillot I, Cuisenier J et al. Facteurs ayant déterminé le choix entre mammectomie et traitement conservateur pour cancer du sein entre 1982 et 1990 dans le département de la Côte d'Or. Bull Cancer 1994;81:303-10
4. Chism SE, Brown BS, Hoyle BA. Breast cancer treatment: evolving approaches but stable results. Int J Radiat Oncol Biol Phys 1986;12:2073-8
5. Contesso G, Mouriesse H, Friedman S et al. The importance of histologic grading in long term prognosis of breast cancer. A study of 1010 patients uniformly treated at the Institut Gustave-Roussy. J Clin Oncol 1987;9:1378-86
6. Early Breast Cancer Trialist Collaborative Group. Effect of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,696 women. N Engl J Med 1988;319: 1681-92
7. Early Breast Cancer Trialist Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339:1-15, 71-85
8. Fisher B, Redmond C, Wicherham DL. Doxorubicin containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 1989;7:572-82
9. ICD-O. International Classification of Disease, 2nd edition. Genève: World Health Organisation, 1990
10. INSEE. Recensement 1990. Paris 1990. Paris: INSEE, 1991
11. International Union Against Cancer. TNM Classification of Malignant Tumours, 4th Edition. New York: Springer-Verlag, 1987
12. Moller-Jensen O, Estève J, Moller H et al. Cancer in the European Community and its Member States. Eur J Cancer 1990;26:1167-1256
13. Olivotto IA, Bajdik CD, Math M et al. Adjuvant systemic treatment and survival after breast cancer. N Engl J Med 1994;330:805-10
14. Parkin DM, Muir CS, Whelan SL et al. Cancer Incidence in Five Continents 6. IARC Scientific publications 1992:120
15. Sasco AJ, Chaplain G, Amoros E et al. Endometrial cancer following breast cancer. Effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;1, à paraître